Oral IgA-IgG treatment of chronic non-specific diarrhoea in infants and children.
The effect of orally administered immunoglobulin (IgAbulin) on chronic non-specific diarrhoea of infancy was studied in seven children, median age 26 (21-36) months and duration of diarrhoea 32 (18-84) weeks. Routine laboratory tests for malabsorption and small bowel biopsies were taken in all children before and after 3 weeks of IgAbulin treatment. The biopsy specimens were analysed with regard to histopathology, electronmicroscopy, immunohistochemistry and microbiology. The number of stools decreased from a median of 4.0 (3.0-5.0) to 1.5 (1.0 3.5) (p < 0.05) stools per day over the study period.
Casswall
T H
TH
Department of Clinical Sciences, Karolinska Institute, Huddinge Hospital, Sweden.
Hammarström
L
L
Veress
B
B
Nord
C E
CE
Bogstedt
A
A
Brockstedt
U
U
Dahlström
K A
KA
D000284:Administration, Oral; D002675:Child, Preschool; D002908:Chronic Disease; D003968:Diarrhea, Infantile / Q000276:immunology / Q000628:therapy*; D005243:Feces / Q000737:chemistry; D006801:Humans; D007070:Immunoglobulin A / Q000008:administration & dosage* / Q000032:analysis; D007074:Immunoglobulin G / Q000008:administration & dosage* / Q000032:analysis; D007223:Infant; D007408:Intestinal Absorption; D007422:Intestines / Q000382:microbiology / Q000473:pathology; D011446:Prospective Studies
D007070:Immunoglobulin A; D007074:Immunoglobulin G